ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.3 Cr (-22.2% YoY) and a net loss of ₹1.2 Cr for Q2 FY27.
Aspira Pathlab & Diagnostics will hold a board meeting on November 6, 2026 to consider unaudited standalone results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after the results.
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Listing Regulations.
Promoter Jay Arvind Bhanushali acquired 1,424 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. The transaction is valued at ₹0.02 Crore.
Promoter Jay Arvind Bhanushali acquired 1,424 shares of Aspira Pathlab & Diagnostics Ltd via the open market. This transaction increased the promoter's stake from 7.27% to 7.28%.
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Promoter Jay Arvind Bhanushali acquired 1,387 equity shares of Aspira Pathlab & Diagnostics Ltd through market purchase, increasing their stake from 7.25% to 7.27%.
Promoter Jay Arvind Bhanushali acquired 1,387 shares of Aspira Pathlab & Diagnostics Ltd via an open-market transaction, increasing his stake by 0.02%.
Promoter Jay Arvind Bhanushali acquired 74 shares of Aspira Pathlab & Diagnostics Ltd via market purchase on September 10, 2026.
Aspira Pathlab approved raising funds of up to ₹65 Crore via a Rights Issue to eligible shareholders. A committee was constituted to oversee the process.
Aspira Pathlab will hold a board meeting on 12 Sep 2026 to consider a capital raise via preferential issue, private placement, or rights issue. No amount or terms are yet specified.
Promoter Jay Arvind Bhanushali acquired 957 shares of Aspira Pathlab & Diagnostics Ltd via market purchase for ₹0.01 Crore.
Jay Arvind Bhanushali (Promoter) acquired 623 equity shares of Aspira Pathlab & Diagnostics Ltd via open market, increasing his holding slightly.
Aspira Pathlab & Diagnostics has dispatched the annual report web-link to shareholders who haven't registered their email addresses, in compliance with SEBI Regulation 36(1)(b).
Aspira Pathlab & Diagnostics Ltd has submitted its 53rd Annual Report and AGM Notice for the financial year 2025-26 to the exchange.
Aspira Pathlab & Diagnostics Ltd announced its 53rd Annual General Meeting to be held on September 25, 2026, with associated book closure and e-voting dates.
Promoter Jay Arvind Bhanushali acquired 332 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. This insider trading disclosure reports a value of ₹0.0029 Crore.
Jay Arvind Bhanushali, a promoter of Aspira Pathlab & Diagnostics Ltd, acquired 332 equity shares through the open market. This transaction increased the promoter's total holding from 7.23% to 7.24%.
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.2 Cr (+19.2% YoY) and net profit of ₹0 Cr for Q1 FY27.
Aspira Pathlab & Diagnostics will hold a board meeting on August 12, 2026, to approve its Q1 financial results and discuss a potential fund-raising proposal.
Mr. Pankaj Jashwant Shah has resigned as Managing Director and Chief Executive Director of Aspira Pathlab & Diagnostics Limited, effective from August 03, 2026.
Mr. Vaibhav Odhekar has resigned as Additional Executive Director of Aspira Pathlab & Diagnostics Limited, effective from the close of business hours on July 25, 2026.
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per regulatory requirements.
Aspira Pathlab reclassified Mr. Nikunj Mange and Mr. Jay Bhanushali as Promoters post-Open Offer. This change in promoter category may impact governance and control dynamics.
Shraddha Jagdish Bhanushali and PACs acquired 22,82,507 shares (22.18% stake) via an open offer. This increases the promoter group's total holding to 46.00%.
Promoter Deepali Arvind Bhanushali acquired 85,443 shares (0.83%) in Aspira Pathlab via an open offer. This increases the promoter group's total stake to 46.00%.
Promoter group acquired 22.18% stake in Aspira Pathlab via an open offer. This increases their holding to 46%, signaling consolidation of control.
Aspira Pathlab & Diagnostics filed its Annual Secretarial Compliance Report for FY2026. The report by independent auditors confirms company compliance with SEBI regulatory requirements.
Aspira Pathlab appointed Mr. Vaibhav Odhekar as Executive Director for five years. Mrs. Neetu Maurya joins as Company Secretary, strengthening corporate governance and leadership.
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.5 Cr (+12.1% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.